GSK/Adolor's Entereg Eligible For Approval, But Lacks Proper Risk Management Plan, Advisory Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Entereg NDA has Feb. 10 user fee date for gastrointestinal recovery after bowel resection surgery.
You may also be interested in...
Entereg Documents Offer Detailed Insight Into REMS Review Process
GlaxoSmithKline's urgent communication during Entereg's second review cycle set into motion a process to resolve safety concerns that would eventually manifest in one of the strongest Risk Evaluation and Mitigation Strategy programs to date.
Entereg Documents Offer Detailed Insight Into REMS Review Process
GlaxoSmithKline's urgent communication during Entereg's second review cycle set into motion a process to resolve safety concerns that would eventually manifest in one of the strongest Risk Evaluation and Mitigation Strategy programs to date.
Adolor/GSK’s Entereg Approved By FDA
Cleared at last, hospital constipation drug brings risk management plan.